UK biotech firm confirms Nasdaq float

Nycomed Amersham, a UK biotech company, confirmed plans for a flotation of its drug discovery unit on Nasdaq in the US in March.

The UK firm filed with the US Securities & Exchange Commission in October last year to float 10% of APBiotech on the US market.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump